华北制药(600812.SH)：他克莫司胶囊获得《药品注册证书》

Core Viewpoint - North China Pharmaceutical (600812.SH) has received approval from the National Medical Products Administration for the registration of Tacrolimus capsules (0.5mg, 1mg), a potent immunosuppressant used to prevent organ rejection after liver or kidney transplants [1]. Company Summary - The approved product, Tacrolimus, is designed to inhibit the formation of cytotoxic lymphocytes, which are the primary factors in graft rejection [1]. - Tacrolimus is indicated for use in preventing graft rejection after liver or kidney transplants, particularly when other immunosuppressive medications are ineffective [1].